| Trial ID: | L5717 |
| Source ID: | NCT05359432
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Empagliflozin|DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: Glycosylated hemoglobin A1c (HbA1c), 24 weeks|High-density lipoprotein (HDL) levels, 24 weeks|Systolic blood pressure, 24 weeks|Fasting blood sugars, 24 weeks|Bodyweight, 24 weeks|Serum creatinine, 24 weeks|Serum glutamic-pyruvic transaminase (SGPT), 24 weeks|Low-density lipoprotein cholesterol, 24 weeks|Total cholesterols, 24 weeks|Serum triglycerides, 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Getz Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-07-01
|
| Completion Date: |
2021-08-18
|
| Results First Posted: |
|
| Last Update Posted: |
2022-05-03
|
| Locations: |
Department of Diabetes and Endocrinology at Sindh Government Hospital New Karachi & Dr. Riasat Medical Center Allah Wala Town, Karachi, Pakistan, Karachi, Sindh, 75330, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT05359432
|
